The GPS immunotherapeutic agent demonstrated preliminary alerts of efficacy in AML.
Amongst sufferers with acute myeloid leukemia (AML) in remission following second-line salvage remedy, the immunotherapeutic agent galinpepimut-S (GPS) demonstrated preliminary alerts of efficacy and particular T-Cell immune responses within the pivotal section 3 REGAL trial, based on a press launch from SELLAS Life Sciences Group, Inc.
After a median follow-up of 13.5 months, fewer than half of sufferers enrolled within the REGAL trial had been confirmed deceased. These outcomes indicated a median survival of over 13.5 months in contrast with the historic median survival from an analogous section 2 examine of solely six months for standard remedy.
Based mostly on these findings, the Unbiased Knowledge Monitoring Committee (IDMC) has advisable the continuation of the medical trial with none modifications. Notably, the IDMC went on to share that the agent exceeded predetermined futility standards.
“Based mostly on all out there information, we consider that GPS may turn into a transformative remedy possibility for AML, providing hope to sufferers with restricted selections, particularly these with relapsed or refractory illness. We’re optimistic in regards to the IDMC’s suggestion to proceed the examine with out modifications and diligently making ready for the Biologics License Software (BLA),” stated Dr. Angelos Stergiou, President and Chief Govt Officer of SELLAS, within the information launch. “Importantly, the REGAL trial offers a transparent and easy path towards in search of regulatory approval for sufferers with AML of their second full remission.”
Moreover, 80% of randomly chosen sufferers enrolled on the REGAL who obtained GPS exhibited T-cell immune response, outperforming the findings from the earlier section 2 examine.
No new security considerations had been famous all through the length of the trial.
These efficacy outcomes are in line with the findings of earlier GPS trials. As such, within the section 2 examine of sufferers with AML in second full remission, the median total survival (OS) for GPS-treated sufferers was 21 months, in contrast with 5.4 months for sufferers receiving standard-of-care remedy, with a 64% GPS-specific immune response.
Allogeneic stem cell transplantation (allo-SCT) holds promise for curing some sufferers with relapsed or refractory AML who can obtain a second or extra remissions with salvage remedy. Nevertheless, a number of obstacles hinder transplantation, and never all sufferers with relapsed or refractory AML are eligible to proceed to allo-SCT.
At the moment, no drug has been authorized for the upkeep of remission in sufferers with AML following second-line salvage remedy, which additional emphasizes the significance of this improvement, based on the information launch.
GPS is a sort of most cancers vaccine that makes use of items of a protein referred to as WT1, which is usually present in most cancers cells, based on the SELLAS web site. Moreover, the vaccine is designed to assist the physique’s immune system create a robust innate immune response and combat most cancers cells which have this protein, based on the Nationwide Most cancers Institute’s web site.
The REGAL section 3 examine is an open-label registrational medical trial evaluating the efficacy of GPS in sufferers with AML who’ve achieved full remission following second-line salvage remedy.
A last evaluation to verify the efficacy of GPS will probably be carried out as soon as 80 occasions, or deaths, have occurred, which is predicted to happen this yr, the trial anticipates, based on the discharge.
The first finish purpose of the examine was OS.
“The interim outcomes symbolize a serious step ahead within the remedy of AML, providing hope for sufferers in remission,” Dr. Yair Levy, Director of Hematologic Malignancies Analysis at Texas Oncology Baylor College Medical Middle, in Dallas, stated within the information launch. “I’m very hopeful that we are going to see a brand new commonplace of care in treating AML sufferers based mostly on the outcomes we’ve noticed in earlier GPS trials.”
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
